FDA
-
-
-
-
-
-
-
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunothe
-
-
-
-
-
-
-
Seagen (SGEN) Reports PADCEV and KEYTRUDA Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 T
-
-
-
-
-
-
-
Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
-
-
-
-
-
-
-
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin
-
-
-
-
-
-
-
Pfizer Invests $43 Billion to Battle Cancer
-
-
-
-
-
-
-
Merck (MRK), Seagen (SGEN) and Astellas Announce FDA Acceptance of sBLA for PADCEV with KEYTRUDA
-
-
-
-
-
-
-
Seagen Reports Third Quarter 2022 Financial Results
-
251,368 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All